IN2014KN02423A - - Google Patents

Info

Publication number
IN2014KN02423A
IN2014KN02423A IN2423KON2014A IN2014KN02423A IN 2014KN02423 A IN2014KN02423 A IN 2014KN02423A IN 2423KON2014 A IN2423KON2014 A IN 2423KON2014A IN 2014KN02423 A IN2014KN02423 A IN 2014KN02423A
Authority
IN
India
Prior art keywords
present
compounds
abc
cftr
transporters
Prior art date
Application number
Other languages
English (en)
Inventor
Sara S Hadida Ruah
Peter D J Grootenhuis
Frederick Van Goor
Jinglan Zhou
Brian Bear
Mark T Miller
Jason Mccartney
Mehdi Michel Jamel Numa
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of IN2014KN02423A publication Critical patent/IN2014KN02423A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Ā -Ā C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Ā -Ā C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
IN2423KON2014 2006-04-07 2007-04-09 IN2014KN02423A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79045906P 2006-04-07 2006-04-07
PCT/US2007/008975 WO2007117715A2 (en) 2006-04-07 2007-04-09 Modulators of atp-binding cassette transporters

Publications (1)

Publication Number Publication Date
IN2014KN02423A true IN2014KN02423A (zh) 2015-05-01

Family

ID=38477342

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2423KON2014 IN2014KN02423A (zh) 2006-04-07 2007-04-09

Country Status (22)

Country Link
US (9) US7776905B2 (zh)
EP (5) EP2007756B1 (zh)
JP (3) JP5420395B2 (zh)
CN (2) CN101460489A (zh)
AU (1) AU2007235260B2 (zh)
BR (1) BRPI0710965B8 (zh)
CA (2) CA2869945C (zh)
CY (3) CY1116979T1 (zh)
DK (3) DK2007756T3 (zh)
ES (4) ES2882684T3 (zh)
HU (4) HUE036165T2 (zh)
IL (1) IL194576A (zh)
IN (1) IN2014KN02423A (zh)
LT (1) LT3091011T (zh)
MX (1) MX2008012945A (zh)
NZ (3) NZ596889A (zh)
PL (4) PL3327016T3 (zh)
PT (3) PT2674428T (zh)
RU (1) RU2451018C2 (zh)
SI (4) SI3327016T1 (zh)
WO (1) WO2007117715A2 (zh)
ZA (1) ZA200809290B (zh)

Families Citing this family (106)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP1664006A2 (en) 2003-09-06 2006-06-07 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
RU2006120549A (ru) * 2003-11-14 2007-12-27 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ (Us) Š¢ŠøŠ°Š·Š¾Š»Ń‹ Šø Š¾ŠŗсŠ°Š·Š¾Š»Ń‹, ŠæрŠøŠ¼ŠµŠ½ŃŠµŠ¼Ń‹Šµ Š² ŠŗŠ°Ń‡ŠµŃŃ‚Š²Šµ Š¼Š¾Š“уŠ»ŃŃ‚Š¾Ń€Š¾Š² трŠ°Š½ŃŠæŠ¾Ń€Ń‚ŠµŃ€Š¾Š² Š°Ń€Ń‚-сŠ²ŃŠ·Ń‹Š²Š°ŃŽŃ‰ŠµŠ¹ ŠŗŠ°ŃŃŠµŃ‚Ń‹
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
CA2810655C (en) 2004-06-24 2013-12-10 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
EP1912983B1 (en) 2005-08-11 2011-06-08 Vertex Pharmaceuticals, Inc. Modulators of cystic fibrosis transmembrane conductance regulator
SI2395002T1 (sl) * 2005-11-08 2014-10-30 Vertex Pharmaceuticals Incorporated Farmacevtski sestavek, vsebujoč heterociklični modulator prenaŔalcev z ATP-vezavno kaseto
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP3708564A1 (en) 2005-12-28 2020-09-16 Vertex Pharmaceuticals Incorporated A solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CN103214450B (zh) * 2005-12-28 2016-10-05 弗ē‰¹å…‹ę–ÆčÆå“ęœ‰é™å…¬åø 作äøŗatp-ē»“合ē›’č½¬čæč›‹ē™½č°ƒčŠ‚剂ēš„1-(č‹Æ并[d][1,3]é—“äŗŒę°§ę‚ēŽÆꈊēƒÆ-5-åŸŗ)-n-(č‹ÆåŸŗ)ēŽÆäø™ēƒ·-ē”²é…°čƒŗč”ē”Ÿē‰©
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
EP2007756B1 (en) 2006-04-07 2015-08-26 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
WO2008127399A2 (en) * 2006-11-03 2008-10-23 Vertex Pharmaceuticals Incorporated Azaindole derivatives as cftr modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
KR20100016073A (ko) * 2007-04-02 2010-02-12 ģøģŠ¤ķ‹°ķŠœķŠø ķ¬ ģ›ģ›”ė“œ ķ—¬ģŠ¤ ļ¼£ļ½†ļ½”ļ½’ ģ–µģ œģ œ ķ™”ķ•©ė¬¼ ė° ģ“ģ˜ ģš©ė„
JP5497633B2 (ja) 2007-05-09 2014-05-21 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼£ļ½†ļ½”ļ½’ć®ćƒ¢ć‚øćƒ„ćƒ¬ćƒ¼ć‚æćƒ¼
EP2158183A2 (en) * 2007-05-25 2010-03-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
CA2696298C (en) 2007-08-24 2016-09-06 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
ES2658064T3 (es) 2007-11-16 2018-03-08 Vertex Pharmaceuticals Incorporated Moduladores de isoquinolina de transportadores de casete de uniĆ³n a ATP
PL2639223T3 (pl) 2007-12-07 2017-09-29 Vertex Pharmaceuticals Incorporated SposĆ³b wytwarzania kwasĆ³w cykloalkilokarboksyamido-pirydyno-benzoesowych
EA201070699A1 (ru) * 2007-12-07 2011-02-28 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ ŠšŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø 3-(6-(1-2,2-Š“ŠøфтŠ¾Ń€Š±ŠµŠ½Š·Š¾[d][1,3]Š“ŠøŠ¾ŠŗсŠ¾Š»-5-ŠøŠ»)цŠøŠŗŠ»Š¾ŠæрŠ¾ŠæŠ°Š½ŠŗŠ°Ń€Š±Š¾ŠŗсŠ°Š¼ŠøŠ“Š¾)-3-Š¼ŠµŃ‚ŠøŠ»ŠæŠøрŠøŠ“ŠøŠ½-2-ŠøŠ»)Š±ŠµŠ½Š·Š¾Š¹Š½Š¾Š¹ ŠŗŠøсŠ»Š¾Ń‚Ń‹
SI2225230T1 (sl) 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP2078711A1 (en) * 2007-12-28 2009-07-15 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor
CA2931134C (en) 2008-02-28 2019-07-30 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
EP2980077B1 (en) 2008-03-31 2020-05-06 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as cftr modulators
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
WO2009131957A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
JP2012503005A (ja) * 2008-09-19 2012-02-02 ć‚¤ćƒ³ć‚¹ćƒ†ć‚£ćƒ†ćƒ„ćƒ¼ćƒˆ ćƒ•ć‚©ć‚¢ ćƒÆćƒ³ćƒÆćƒ¼ćƒ«ćƒ‰ ćƒ˜ćƒ«ć‚¹ ć‚¤ćƒŸćƒ€ć‚¾ćƒ¼ćƒ«čŖ˜å°Žä½“ćŠć‚ˆć³ćƒˆćƒŖć‚¢ć‚¾ćƒ¼ćƒ«čŖ˜å°Žä½“ć‚’å«ć‚€ć€åŒ–åˆē‰©ć€ēµ„ęˆē‰©ćŖć‚‰ć³ć«ę–¹ę³•ć€‚
WO2010037066A2 (en) 2008-09-29 2010-04-01 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
SI2349263T1 (sl) * 2008-10-23 2014-09-30 Vertex Pharmaceuticals Incorporated Modulatorji cistiĆ¤Å›no-fibroznega transmembranskega regulatorja prevodnosti
NZ609962A (en) * 2008-11-06 2014-11-28 Vertex Pharma Modulators of atp-binding cassette transporters
UA104876C2 (uk) * 2008-11-06 2014-03-25 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚Ń–ŠŗŠ°Š»Š· Š†Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ ŠœŠ¾Š“уŠ»ŃŃ‚Š¾Ń€Šø atф-Š·Š²'яŠ·ŃƒŠ²Š°Š»ŃŒŠ½Šøх ŠŗŠ°ŃŠµŃ‚Š½Šøх трŠ°Š½ŃŠæŠ¾Ń€Ń‚ŠµŃ€Ń–Š²
KR101852173B1 (ko) 2009-03-20 2018-04-27 ė²„ķ…ģŠ¤ ķŒŒė§ˆģŠˆķ‹°ģ¹¼ģŠ¤ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ė‚­ģ„± ģ„¬ģœ ģ¦ ė§‰ķš”ė‹Ø ģ „ė„ė„ ģ”°ģ ˆģžģ˜ ģ”°ģ •ģžģ˜ ģ œģ”° ė°©ė²•
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US8497271B2 (en) 2009-10-07 2013-07-30 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8304577B2 (en) 2009-10-09 2012-11-06 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
ES2604105T3 (es) * 2010-03-25 2017-03-03 Vertex Pharmaceuticals Incorporated Formula cristalina de (r) -1 (2,2- difluorobenzo [d] [1,3] dioxol - 5yl) - n- (1- (2,3 - dihidroxipropil) - 6 - fluoro - 2- (1 - hydroxy-2-metilpropan-2il) -1h-indol-5il) cyclopropanecarboxamida
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN102933206A (zh) 2010-04-07 2013-02-13 弗ē‰¹å…‹ę–ÆčÆå“ęœ‰é™å…¬åø 3-(6-(1-(2ļ¼Œ2-äŗŒę°Ÿč‹Æ并[d][1ļ¼Œ3]äŗŒę°§ę‚ēŽÆꈊēƒÆ-5-åŸŗ)ēŽÆäø™ēƒ·ē”²é…°čƒŗåŸŗ)-3-ē”²åŸŗ吔啶-2-åŸŗ)č‹Æē”²é…øēš„å›ŗ体形式
JP2013523833A (ja) 2010-04-07 2013-06-17 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼“āˆ’ļ¼ˆļ¼–āˆ’ļ¼ˆļ¼‘āˆ’ļ¼ˆļ¼’ļ¼Œļ¼’āˆ’ć‚øćƒ•ćƒ«ć‚Ŗćƒ­ćƒ™ćƒ³ć‚¾ļ¼»ļ½„ļ¼½ļ¼»ļ¼‘ļ¼Œļ¼“ļ¼½ć‚øć‚Ŗć‚­ć‚½ćƒ¼ćƒ«āˆ’ļ¼•āˆ’ć‚¤ćƒ«ļ¼‰ć‚·ć‚Æćƒ­ćƒ—ćƒ­ćƒ‘ćƒ³ć‚«ćƒ«ćƒœć‚­ć‚µćƒŸćƒ‰ļ¼‰āˆ’ļ¼“āˆ’ćƒ”ćƒćƒ«ćƒ”ćƒŖć‚øćƒ³āˆ’ļ¼’āˆ’ć‚¤ćƒ«ļ¼‰å®‰ęÆ香é…øć®åŒ»č–¬ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ęŠ•äøŽ
WO2011133956A1 (en) * 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
CA2796602A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
AU2011242452A1 (en) * 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
MX342288B (es) 2010-04-22 2016-09-23 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
NZ603386A (en) 2010-05-20 2015-02-27 Vertex Pharma Pharmaceutical compositions and administrations thereof
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
RU2013112937A (ru) * 2010-08-23 2014-09-27 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ Š¤Š°Ń€Š¼Š°Ń†ŠµŠ²Ń‚ŠøчŠµŃŠŗŠøŠµ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø (r)-1-(2, 2-Š“ŠøфтŠ¾Ń€Š±ŠµŠ½Š·Š¾[d][1, 3]Š“ŠøŠ¾ŠŗсŠ¾Š»-5-ŠøŠ»)-n-(2, 3-Š“ŠøŠ³ŠøŠ“рŠ¾ŠŗсŠøŠæрŠ¾ŠæŠøŠ»)-6-фтŠ¾Ń€-2-(1-Š³ŠøŠ“рŠ¾ŠŗсŠø-2-Š¼ŠµŃ‚ŠøŠ»ŠæрŠ¾ŠæŠ°Š½-2-ŠøŠ»)-1Š½-ŠøŠ½Š“Š¾Š»-5-ŠøŠ»)цŠøŠŗŠ»Š¾ŠæрŠ¾ŠæŠ°Š½ŠŗŠ°Ń€Š±Š¾ŠŗсŠ°Š¼ŠøŠ“Š° Šø Šøх ŠæрŠøŠ¼ŠµŠ½ŠµŠ½ŠøŠµ
CN102133402B (zh) * 2011-03-24 2013-06-12 首都医ē§‘大学附属北äŗ¬åŒä»åŒ»é™¢ å›Šę€§ēŗ¤ē»“化č·Øč†œč½¬åÆ¼č°ƒčŠ‚å› å­ęŠ‘åˆ¶å‰‚åœØåˆ¶å¤‡ę²»ē–—ē³–å°æē—…čÆē‰©äø­ēš„åŗ”ē”Ø
EP2773349A1 (en) 2011-11-02 2014-09-10 Vertex Pharmaceuticals Incorporated Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl]- 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide) for treating cftr mediated diseases
IN2014KN00885A (zh) * 2011-11-08 2015-10-02 Vertex Pharma
CN104470518A (zh) 2012-02-27 2015-03-25 ę²ƒę³°å…‹ę–ÆčÆē‰©č‚”ä»½ęœ‰é™å…¬åø čÆē‰©ē»„合ē‰©åŠå…¶ę–½ē”Ø
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CA2873214C (en) 2012-05-11 2021-02-16 Reset Therapeutics, Inc. Carbazole-containing sulfonamides as cryptochrome modulators
EP2858645A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
CN102816104B (zh) * 2012-08-30 2014-05-21 ęµ™ę±Ÿå¤§å­¦ äø€ē§3-ę°°åŸŗ吲哚ē±»åŒ–合ē‰©ēš„åˆęˆę–¹ę³•
ITMI20122065A1 (it) 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
EP2958924B1 (en) 2013-02-22 2016-12-28 Bristol-Myers Squibb Company 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1)
WO2015006100A1 (en) 2013-07-08 2015-01-15 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
RU2016122882A (ru) 2013-11-12 2017-12-19 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ Š”ŠæŠ¾ŃŠ¾Š± ŠæŠ¾Š»ŃƒŃ‡ŠµŠ½Šøя фŠ°Ń€Š¼Š°Ń†ŠµŠ²Ń‚ŠøчŠµŃŠŗŠøх ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠ¹ Š“Š»Ń Š»ŠµŃ‡ŠµŠ½Šøя Š¾ŠæŠ¾ŃŃ€ŠµŠ“Š¾Š²Š°Š½Š½Ń‹Ń… cftr Š·Š°Š±Š¾Š»ŠµŠ²Š°Š½ŠøŠ¹
TWI690521B (zh) 2014-04-07 2020-04-11 ē¾Žå•†åŒę­„č£½č—„å…¬åø 作ē‚ŗéš±čŠ±č‰²ē“ čŖæēÆ€åŠ‘ä¹‹å«ęœ‰å’”å”‘ä¹‹é†Æčƒŗ锞态čƒŗåŸŗē”²é…øé…Æé”žåŠč„²é”ž
CN103922934B (zh) * 2014-04-11 2016-03-30 北äŗ¬ä¹åØę³°å…‹åŒ»čÆꊀęœÆęœ‰é™å…¬åø ę“»ę³¼äŗšē”²åŸŗ化合ē‰©ēš„ēƒ·åŸŗåŒ–ę–¹ę³•
ES2957761T3 (es) 2014-04-15 2024-01-25 Vertex Pharma Composiciones farmacƩuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quƭstica
RU2020134082A (ru) 2014-10-06 2020-11-27 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ ŠœŠ¾Š“уŠ»ŃŃ‚Š¾Ń€Ń‹ рŠµŠ³ŃƒŠ»ŃŃ‚Š¾Ń€Š° трŠ°Š½ŃŠ¼ŠµŠ¼Š±Ń€Š°Š½Š½Š¾Š¹ ŠæрŠ¾Š²Š¾Š“ŠøŠ¼Š¾ŃŃ‚Šø ŠæрŠø Š¼ŃƒŠŗŠ¾Š²ŠøсцŠøŠ“Š¾Š·Šµ
JP6746569B2 (ja) 2014-10-07 2020-08-26 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ļ¼¶ļ½…ļ½’ļ½”ļ½…ļ½˜ ļ¼°ļ½ˆļ½ļ½’ļ½ļ½ļ½ƒļ½…ļ½•ļ½”ļ½‰ļ½ƒļ½ļ½Œļ½“ ļ¼©ļ½Žļ½ƒļ½ļ½’ļ½ļ½ļ½’ļ½ļ½”ļ½…ļ½„ åš¢čƒžę€§ē·šē¶­ē—‡č†œč²«é€šć‚³ćƒ³ćƒ€ć‚Æć‚æćƒ³ć‚¹åˆ¶å¾”å› å­ć®ćƒ¢ć‚øćƒ„ćƒ¬ćƒ¼ć‚æćƒ¼ć®å…±ēµę™¶
CA3191010A1 (en) * 2014-10-31 2016-05-06 AbbVie Global Enterprises Ltd. Substituted chromanes and method of use
RU2691136C2 (ru) 2014-11-18 2019-06-11 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ Š”ŠæŠ¾ŃŠ¾Š± ŠæрŠ¾Š²ŠµŠ“ŠµŠ½Šøя Š²Ń‹ŃŠ¾ŠŗŠ¾ŠæрŠ¾ŠøŠ·Š²Š¾Š“ŠøтŠµŠ»ŃŒŠ½Š¾Š¹ тŠµŃŃ‚Š¾Š²Š¾Š¹ Š²Ń‹ŃŠ¾ŠŗŠ¾ŃŃ„Ń„ŠµŠŗтŠøŠ²Š½Š¾Š¹ Š¶ŠøŠ“ŠŗŠ¾ŃŃ‚Š½Š¾Š¹ хрŠ¾Š¼Š°Ń‚Š¾Š³Ń€Š°Ń„ŠøŠø
WO2016160945A1 (en) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Deuterated vx-661
EP3292124B1 (en) 2015-04-10 2019-05-22 Bristol-Myers Squibb Company 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors
CN105153105B (zh) * 2015-08-15 2018-01-19 ęµ™ę±Ÿę°ø宁čÆäøšč‚”ä»½ęœ‰é™å…¬åø 1ā€‘(2,2ā€‘äŗŒę°Ÿč‹Æ并[d][1,3]äŗŒę°§ę‚ēŽÆꈊēƒÆā€‘5ā€‘åŸŗ)ēŽÆäø™ēƒ·ē”²é…øēš„åˆęˆę–¹ę³•åŠå…¶äø­é—“体
SI3519401T1 (sl) 2016-09-30 2022-01-31 Vertex Pharmaceuticals Incorporated Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
DK3551622T3 (da) 2016-12-09 2020-11-23 Vertex Pharma Modulator af transmembrankonduktansregulator af cystisk fibrose, farmaceutiske sammensƦtninger, behandlingsfremgangsmƄder og fremgangsmƄde til fremstilling af modulatoren
EP3634402A1 (en) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AR112467A1 (es) 2017-08-02 2019-10-30 Vertex Pharma Procesos para preparar compuestos
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
EP3709986B1 (en) 2017-11-14 2023-11-01 Merck Sharp & Dohme LLC Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
CN111344287B (zh) 2017-11-14 2023-12-19 é»˜ę²™äøœęœ‰é™č“£ä»»å…¬åø 作äøŗ吲哚čƒŗ2ļ¼Œ3-åŒåŠ ę°§é…¶(ido)ęŠ‘åˆ¶å‰‚ēš„ę–°åž‹å–ä»£ēš„č”čŠ³åŸŗ化合ē‰©
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 ē¾Žå•†ē¶­ę³°å…‹ę–Æč£½č—„å…¬åø ē”Øę–¼ę²»ē™‚å›Šč…«ēŗ–化ē—‡ä¹‹é†«č—„ēµ„合ē‰©
LT3752510T (lt) 2018-02-15 2023-04-11 Vertex Pharmaceuticals Incorporated Makrocikliniai junginiai kaip cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai, jų farmacinės kompozicijos, jų panaudojimas cistinės fibrozės gydymui ir jų gamybos būdas
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
RS65335B1 (sr) 2018-10-05 2024-04-30 Annapurna Bio Inc Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnoÅ”cĢu receptora apj
CN109880090A (zh) * 2019-02-18 2019-06-14 华ē ”(佛山)ēŗ³ē±³ęę–™ęœ‰é™å…¬åø äø€ē§å«ēŸ³å¢ØēƒÆ仄及ē¢³ēŗ³ē±³ē®”ēš„聚酰äŗščƒŗåƼēƒ­ęę–™ć€åƼēƒ­č†œåŠå…¶åˆ¶å¤‡ę–¹ę³•
JP2022544383A (ja) 2019-08-14 2022-10-18 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼£ļ½†ļ½”ļ½’ćƒ¢ć‚øćƒ„ćƒ¬ćƒ¼ć‚æ恮ēµę™¶å½¢ę…‹
TW202115092A (zh) 2019-08-14 2021-04-16 ē¾Žå•†ē¶­ę³°å…‹ę–Æč£½č—„å…¬åø å›Šč…«ēŗ–ē¶­åŒ–č·Øč†œå‚³å°ŽčŖæēÆ€č›‹ē™½ä¹‹čŖæēƀ劑
TW202120517A (zh) 2019-08-14 2021-06-01 ē¾Žå•†ē¶­ę³°å…‹ę–Æč£½č—„å…¬åø č£½å‚™cftrčŖæēÆ€åŠ‘ä¹‹ę–¹ę³•
CN113748716B (zh) * 2020-03-31 2022-10-28 华äøŗꊀęœÆęœ‰é™å…¬åø 小åŒŗꐜē“¢ēš„ę–¹ę³•ć€č£…ē½®åŠ***
BR112023002651A2 (pt) 2020-08-20 2023-04-04 Univ Leland Stanford Junior MĆ©todos de tratamento de doenƧas respiratĆ³rias definidas por hipersecreĆ§Ć£o de muco
CN112851493B (zh) * 2020-11-10 2022-09-06 å°å·žč‡»ęŒšē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§2,4,5-äø‰ę°Ÿč‹Æ乙é…øēš„åˆ¶å¤‡ę–¹ę³•
DE102021207925A1 (de) * 2021-07-23 2023-01-26 Continental Reifen Deutschland Gmbh Verbindung, Verfahren zu deren Herstellung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Ozonschutzmittel und/oder Farbstoff
WO2024056798A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators
WO2024056791A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
CN115872895A (zh) * 2023-02-22 2023-03-31 北äŗ¬čÆŗē¦¾č‡“ęŗē§‘ęŠ€č‚”ä»½ęœ‰é™å…¬åø ē”ØäŗŽč”ē”ŸēŸ­é“¾č„‚č‚Ŗé…øę ‡å‡†å“ä½œäøŗå†…ę ‡ēš„é‡ę ‡čÆ•å‰‚åŠå…¶åˆ¶å¤‡ę–¹ę³•ć€åŗ”ē”Ø

Family Cites Families (174)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5328173A (en) 1976-08-06 1978-03-16 Zenyaku Kogyo Kk Novel phenylmethanenitro compound and its preparation
US4138397A (en) 1978-02-27 1979-02-06 Richardson-Merrell Inc. 6-(2,3-Dihydro-5-benzofuranyl)acetamido penicillin derivatives
GB8524157D0 (en) * 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
JPS61103861A (ja) 1984-10-27 1986-05-22 Nitto Kasei Kk ć‚¢ćƒŖāˆ’ćƒ«ē½®ę›ć‚·ć‚¢ćƒ³é…¢é…øć‚Øć‚¹ćƒ†ćƒ«ć®č£½é€ ę–¹ę³•
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
WO1998047868A1 (en) 1997-04-18 1998-10-29 Smithkline Beecham Plc Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
ES2247707T3 (es) 1997-06-21 2006-03-01 Roche Diagnostics Gmbh Derivados del acido barbiturico con actividad antimetastasica y antitumoral.
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6426331B1 (en) 1998-07-08 2002-07-30 Tularik Inc. Inhibitors of STAT function
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
WO2001019830A1 (en) 1999-09-10 2001-03-22 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
IT1315267B1 (it) 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
BR0109050A (pt) * 2000-03-09 2004-04-27 Ono Pharmaceutical Co Derivados de indol, processo para prepapaĆ§Ć£o e uso dos mesmos
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6562989B2 (en) 2000-08-07 2003-05-13 Yale University Catalyst for aromatic Cā€”O, Cā€”N, and Cā€”C bond formation
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
AR030357A1 (es) 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP1383799A4 (en) 2001-04-10 2008-08-06 Transtech Pharma Inc PROBES, SYSTEMS AND METHODS FOR DISCOVERING MEDICAMENTS
ATE449763T1 (de) 2001-04-16 2009-12-15 Eisai R&D Man Co Ltd 1h-indazolverbindungen die jnk hemmen
KR100575944B1 (ko) * 2001-06-28 2006-05-02 ķ™”ģ“ģž ķ”„ė”œė•ģø  ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ėÆøģ†Œģ²“ ķŠøė¦¬źø€ė¦¬ģ„øė¼ģ“ė“œ ģ „ė‹¬ ė‹Øė°±ģ§ˆ(ļ½ļ½”ļ½) ė°/ė˜ėŠ”ģ•„ķ¬ģ§€ė°©ė‹Øė°±ģ§ˆ ļ½‚(ļ½ļ½ļ½ ļ½‚)ė¶„ė¹„ģ˜ ģ–µģ œģ œė”œģ„œģ˜ķŠøė¦¬ģ•„ėÆøė“œ-ģ¹˜ķ™˜ėœ ģøėŒ, ė²¤ģ”°ķ‘øėž€ ė° ė²¤ģ”°ķ‹°ģ˜¤ķŽœ
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US20030171411A1 (en) 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
AU2003252478A1 (en) 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
US20060083784A1 (en) 2002-08-07 2006-04-20 Smithkline Beecham Corporation Amorphous pharmaceutical compositions
EA009847B1 (ru) 2002-09-30 2008-04-28 Š”Š·Šµ Š ŠøŠ“Š¶ŠµŠ½Ń‚с ŠžŃ„ Š”Š·Šµ Š®Š½ŠøŠ²ŠµŃ€ŃŠøтŠø ŠžŃ„ ŠšŠ°Š»ŠøфŠ¾Ń€Š½Šøя Š˜Š½Š³ŠøŠ±ŠøтŠ¾Ń€Ń‹ Š±ŠµŠ»ŠŗŠ°-рŠµŠ³ŃƒŠ»ŃŃ‚Š¾Ń€Š° трŠ°Š½ŃŠ¼ŠµŠ¼Š±Ń€Š°Š½Š½Š¾Š¹ ŠæрŠ¾Š²Š¾Š“ŠøŠ¼Š¾ŃŃ‚Šø ŠæрŠø Š¼ŃƒŠŗŠ¾Š²ŠøсцŠøŠ“Š¾Š·Šµ Šø Šøх ŠæрŠøŠ¼ŠµŠ½ŠµŠ½ŠøŠµ
JP2004131393A (ja) 2002-10-08 2004-04-30 Kowa Co ꘓęŗ¶å‡ŗę€§č£½å‰¤
JP4227389B2 (ja) * 2002-10-09 2009-02-18 ęµœę¾ćƒ›ćƒˆćƒ‹ć‚Æć‚¹ę Ŗ式会ē¤¾ ę’®åƒč£…ē½®åŠć³ćć®č£½é€ ę–¹ę³•
US20050215614A1 (en) * 2002-10-15 2005-09-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
FR2846327B1 (fr) 2002-10-25 2006-03-24 Merck Sante Sas Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
WO2004041277A1 (en) * 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
WO2004056744A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
DE10306941A1 (de) 2003-02-18 2004-08-26 Merck Patent Gmbh Benzofuranoxyethylamine
US20050113423A1 (en) * 2003-03-12 2005-05-26 Vangoor Frederick F. Modulators of ATP-binding cassette transporters
MXPA05010444A (es) 2003-04-03 2005-11-04 Merck Patent Gmbh Compuestos de carbonilo.
HUE031794T2 (en) 2003-04-11 2017-08-28 Ptc Therapeutics Inc 1,2,4-oxadiol-benzoic acid compounds and their use for nonsense suppression and disease treatment
US7696244B2 (en) 2003-05-16 2010-04-13 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
EP1646615B1 (en) * 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
AU2004253541B2 (en) 2003-06-27 2010-10-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Amphiphilic pyridinium compounds, method of making and use thereof
NZ544935A (en) * 2003-08-15 2009-08-28 Lundbeck & Co As H Cyclopropyl derivatives as NK3 receptor antagonists
CN1867549B (zh) * 2003-08-15 2011-07-06 HĀ·éš†å¾·č“å…‹ęœ‰é™å…¬åø 作äøŗnk3å—ä½“ę‹®ęŠ—å‰‚ēš„ēŽÆäø™åŸŗč”ē”Ÿē‰©
EP1664006A2 (en) 2003-09-06 2006-06-07 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
RU2006115602A (ru) * 2003-10-08 2007-11-20 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ (Us) ŠœŠ¾Š“уŠ»ŃŃ‚Š¾Ń€Ń‹ ŠæŠµŃ€ŠµŠ½Š¾ŃŃ‡ŠøŠŗŠ¾Š² Š°Ń‚Ń„-сŠ²ŃŠ·Ń‹Š²Š°ŃŽŃ‰Šøх ŠŗŠ°ŃŃŠµŃ‚
WO2005037802A1 (ja) 2003-10-16 2005-04-28 Sankyo Company, Limited ļ¼•ļ¼ć‚¢ćƒŖćƒ¼ćƒ«ćƒ”ćƒŖ惟ć‚øćƒ³čŖ˜å°Žä½“
WO2005040135A1 (ja) 2003-10-24 2005-05-06 Ono Pharmaceutical Co., Ltd. ęŠ—ć‚¹ćƒˆćƒ¬ć‚¹č–¬ćŠć‚ˆć³ćć®åŒ»č–¬ē”Ø途
RU2006120549A (ru) * 2003-11-14 2007-12-27 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ (Us) Š¢ŠøŠ°Š·Š¾Š»Ń‹ Šø Š¾ŠŗсŠ°Š·Š¾Š»Ń‹, ŠæрŠøŠ¼ŠµŠ½ŃŠµŠ¼Ń‹Šµ Š² ŠŗŠ°Ń‡ŠµŃŃ‚Š²Šµ Š¼Š¾Š“уŠ»ŃŃ‚Š¾Ń€Š¾Š² трŠ°Š½ŃŠæŠ¾Ń€Ń‚ŠµŃ€Š¾Š² Š°Ń€Ń‚-сŠ²ŃŠ·Ń‹Š²Š°ŃŽŃ‰ŠµŠ¹ ŠŗŠ°ŃŃŠµŃ‚Ń‹
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2005074650A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
BRPI0509282A (pt) 2004-03-30 2007-09-18 Univ California compostos contendo hidrazida inibidores de cftr e seus usos
US20050222271A1 (en) 2004-03-31 2005-10-06 Le Huang Novel amorphous form of memantine hydrochloride
WO2005117514A2 (en) 2004-06-01 2005-12-15 Tm Bioscience Corporation Method of detecting cystic fibrosis associated mutations
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
US20140343098A1 (en) 2004-06-24 2014-11-20 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CA2810655C (en) 2004-06-24 2013-12-10 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US20060000401A1 (en) 2004-07-01 2006-01-05 Massetti Joseph A Mooring line storage device
AU2005269981A1 (en) 2004-07-02 2006-02-09 Bonck, John A Tablet for pulsed delivery
US8188277B2 (en) 2004-08-06 2012-05-29 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds for suppressing the generation of collagen
DE102004047254A1 (de) 2004-09-29 2006-04-13 Merck Patent Gmbh Carbonylverbindungen
EP2363129A1 (en) 2004-10-13 2011-09-07 PTC Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
MX2007010112A (es) 2005-02-25 2007-10-12 Ono Pharmaceutical Co Compuesto indol y uso del mismo.
US8242149B2 (en) * 2005-03-11 2012-08-14 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
BRPI0608453A2 (pt) 2005-03-18 2009-12-29 Univ California compostos tendo atividade na correĆ§Ć£o de processamento de cftr mutante e usos destes
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
SI2348022T1 (sl) 2005-03-28 2013-05-31 Toyama Chemical Co., Ltd. Postopek proizvodnje 1-(3-(2-(1-benzotiofen-5-il)etoksi)propil)azetidin-3-ola ali soli le-tega
ES2390804T3 (es) 2005-04-08 2012-11-16 Ptc Therapeutics, Inc. Composiciones de un 1,2,4-oxadiazol oralmente activo para terapia de supresiĆ³n de la mutaciĆ³n sin sentido
EP1891018B1 (en) 2005-05-24 2011-11-16 Vertex Pharmaceuticals, Inc. Modulators of atp-binding cassette transporters
ZA200802172B (en) 2005-08-11 2009-06-24 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
EP1912983B1 (en) 2005-08-11 2011-06-08 Vertex Pharmaceuticals, Inc. Modulators of cystic fibrosis transmembrane conductance regulator
CA2619438A1 (en) 2005-08-29 2007-03-08 Irwin C. Jacobs Amorphous solid dispersions of 7-chloro-n,n, 5-trimethyl-4-oxo-3-phenyl-3, 5,-dihydro-4h-pyridazino(4,5-b) indole-1-acetamide
JP2009511494A (ja) 2005-10-06 2009-03-19 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼”ļ½”ļ½ēµåˆć‚«ć‚»ćƒƒćƒˆćƒˆćƒ©ćƒ³ć‚¹ćƒćƒ¼ć‚æćƒ¼ć®ćƒ¢ć‚øćƒ„ćƒ¬ćƒ¼ć‚æćƒ¼
US7401405B2 (en) * 2005-10-11 2008-07-22 Silverbrook Research Pty Ltd Method of fabricating inkjet nozzles having associated ink priming features
US20120232059A1 (en) * 2005-11-08 2012-09-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
SI2395002T1 (sl) * 2005-11-08 2014-10-30 Vertex Pharmaceuticals Incorporated Farmacevtski sestavek, vsebujoč heterociklični modulator prenaŔalcev z ATP-vezavno kaseto
US8030305B2 (en) 2005-12-21 2011-10-04 Janssen Pharmaceutica N.V. Triazolopyridazines as kinase modulators
AU2006331614A1 (en) 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of ABC transporters
EP1974212A1 (en) 2005-12-27 2008-10-01 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CN103214450B (zh) 2005-12-28 2016-10-05 弗ē‰¹å…‹ę–ÆčÆå“ęœ‰é™å…¬åø 作äøŗatp-ē»“合ē›’č½¬čæč›‹ē™½č°ƒčŠ‚剂ēš„1-(č‹Æ并[d][1,3]é—“äŗŒę°§ę‚ēŽÆꈊēƒÆ-5-åŸŗ)-n-(č‹ÆåŸŗ)ēŽÆäø™ēƒ·-ē”²é…°čƒŗč”ē”Ÿē‰©
EP3708564A1 (en) 2005-12-28 2020-09-16 Vertex Pharmaceuticals Incorporated A solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
GEP20125378B (en) 2006-03-20 2012-01-10 Vertex Pharma Pharmaceutical compositions
EP2001498A4 (en) 2006-03-20 2013-01-23 Vertex Pharma PHARMACEUTICAL COMPOSITIONS
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
EP2007756B1 (en) 2006-04-07 2015-08-26 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
ES2377840T3 (es) * 2006-05-12 2012-04-02 Vertex Pharmaceuticals, Inc. Composiciones de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida
JP2010507577A (ja) 2006-10-23 2010-03-11 ć‚Øć‚¹ć‚øćƒ¼ć‚Ø惃ć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗć€ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ 惈ćƒŖć‚¢ć‚¾ćƒ­ćƒ”ćƒŖ惀ć‚øćƒ³ć‚æćƒ³ćƒ‘ć‚Æč³Ŗć‚­ćƒŠćƒ¼ć‚¼ćƒ¢ć‚øćƒ„ćƒ¬ćƒ¼ć‚æćƒ¼
WO2008127399A2 (en) 2006-11-03 2008-10-23 Vertex Pharmaceuticals Incorporated Azaindole derivatives as cftr modulators
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008064259A2 (en) 2006-11-21 2008-05-29 Biokey, Inc. Solid dispersion composition comprising fluvastatin
WO2008065732A1 (fr) 2006-11-27 2008-06-05 Nippon Polyurethane Industry Co., Ltd. ProcƩdƩ de production d'un mƩlange Ơ base d'isocyanate modifiƩ contenant une liaison allophanate et une liaison isocyanurate
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
JP5497633B2 (ja) 2007-05-09 2014-05-21 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼£ļ½†ļ½”ļ½’ć®ćƒ¢ć‚øćƒ„ćƒ¬ćƒ¼ć‚æćƒ¼
CN101687883B (zh) 2007-05-25 2012-05-23 ę²ƒę³°å…‹ę–ÆčÆē‰©č‚”ä»½ęœ‰é™å…¬åø å›Šę€§ēŗ¤ē»“化č·Øč†œä¼ åÆ¼č°ƒčŠ‚å› å­ēš„č°ƒčŠ‚å‰‚
US20110177999A1 (en) * 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
CA2696298C (en) 2007-08-24 2016-09-06 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP2201010B1 (en) * 2007-09-14 2013-11-06 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP2222304A2 (en) 2007-09-14 2010-09-01 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
ES2658064T3 (es) 2007-11-16 2018-03-08 Vertex Pharmaceuticals Incorporated Moduladores de isoquinolina de transportadores de casete de uniĆ³n a ATP
US8227463B2 (en) 2007-11-22 2012-07-24 Zenyaku Kogyo Kabushiki Kaisha Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same
SI2225230T1 (sl) 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
EA201070699A1 (ru) * 2007-12-07 2011-02-28 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ ŠšŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø 3-(6-(1-2,2-Š“ŠøфтŠ¾Ń€Š±ŠµŠ½Š·Š¾[d][1,3]Š“ŠøŠ¾ŠŗсŠ¾Š»-5-ŠøŠ»)цŠøŠŗŠ»Š¾ŠæрŠ¾ŠæŠ°Š½ŠŗŠ°Ń€Š±Š¾ŠŗсŠ°Š¼ŠøŠ“Š¾)-3-Š¼ŠµŃ‚ŠøŠ»ŠæŠøрŠøŠ“ŠøŠ½-2-ŠøŠ»)Š±ŠµŠ½Š·Š¾Š¹Š½Š¾Š¹ ŠŗŠøсŠ»Š¾Ń‚Ń‹
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
PL2639223T3 (pl) 2007-12-07 2017-09-29 Vertex Pharmaceuticals Incorporated SposĆ³b wytwarzania kwasĆ³w cykloalkilokarboksyamido-pirydyno-benzoesowych
EP2231671B1 (en) * 2007-12-13 2013-04-24 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA2931134C (en) 2008-02-28 2019-07-30 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
EP2980077B1 (en) * 2008-03-31 2020-05-06 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as cftr modulators
MX2010011209A (es) 2008-04-24 2010-11-12 Squibb Bristol Myers Co Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer.
EP2328618B1 (en) 2008-08-13 2017-11-29 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4- oxoquinoline-3-carboxamide and administration thereof
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2010037066A2 (en) 2008-09-29 2010-04-01 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
SI2349263T1 (sl) 2008-10-23 2014-09-30 Vertex Pharmaceuticals Incorporated Modulatorji cistiĆ¤Å›no-fibroznega transmembranskega regulatorja prevodnosti
NZ592687A (en) 2008-10-23 2013-04-26 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
NZ592504A (en) * 2008-10-23 2013-04-26 Vertex Pharma Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
US20110257223A1 (en) * 2008-10-23 2011-10-20 Vertex Pharmaceuticals Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
UA104876C2 (uk) 2008-11-06 2014-03-25 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚Ń–ŠŗŠ°Š»Š· Š†Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ ŠœŠ¾Š“уŠ»ŃŃ‚Š¾Ń€Šø atф-Š·Š²'яŠ·ŃƒŠ²Š°Š»ŃŒŠ½Šøх ŠŗŠ°ŃŠµŃ‚Š½Šøх трŠ°Š½ŃŠæŠ¾Ń€Ń‚ŠµŃ€Ń–Š²
NZ609962A (en) 2008-11-06 2014-11-28 Vertex Pharma Modulators of atp-binding cassette transporters
US8367660B2 (en) * 2008-12-30 2013-02-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
KR101852173B1 (ko) 2009-03-20 2018-04-27 ė²„ķ…ģŠ¤ ķŒŒė§ˆģŠˆķ‹°ģ¹¼ģŠ¤ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ė‚­ģ„± ģ„¬ģœ ģ¦ ė§‰ķš”ė‹Ø ģ „ė„ė„ ģ”°ģ ˆģžģ˜ ģ”°ģ •ģžģ˜ ģ œģ”° ė°©ė²•
DK2408749T3 (en) 2009-03-20 2018-08-13 Vertex Pharma CYSTIC FIBROSE TRANSMEMBRAN CONDUCTOR CONTROLLER MODULATORS
KR20120083416A (ko) 2009-09-17 2012-07-25 ė²„ķ…ģŠ¤ ķŒŒė§ˆģŠˆķ‹°ģ¹¼ģŠ¤ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ•„ģžė¹„ģ‹œķ“ė¦­ ķ™”ķ•©ė¬¼ģ˜ ģ œģ”° ė°©ė²•
EP2813227A1 (en) * 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
CA2778492A1 (en) * 2009-10-23 2011-04-28 Vertex Pharmaceuticals Incorporated Process for preparing modulators of cystic fibrosis transmembrane conductance regulator
WO2011050220A1 (en) * 2009-10-23 2011-04-28 Vertex Pharmaceuticals Incorporated Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
US8471029B2 (en) * 2010-03-19 2013-06-25 Vertex Pharmaceutical Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
ES2604105T3 (es) * 2010-03-25 2017-03-03 Vertex Pharmaceuticals Incorporated Formula cristalina de (r) -1 (2,2- difluorobenzo [d] [1,3] dioxol - 5yl) - n- (1- (2,3 - dihidroxipropil) - 6 - fluoro - 2- (1 - hydroxy-2-metilpropan-2il) -1h-indol-5il) cyclopropanecarboxamida
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
JP2013523833A (ja) 2010-04-07 2013-06-17 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼“āˆ’ļ¼ˆļ¼–āˆ’ļ¼ˆļ¼‘āˆ’ļ¼ˆļ¼’ļ¼Œļ¼’āˆ’ć‚øćƒ•ćƒ«ć‚Ŗćƒ­ćƒ™ćƒ³ć‚¾ļ¼»ļ½„ļ¼½ļ¼»ļ¼‘ļ¼Œļ¼“ļ¼½ć‚øć‚Ŗć‚­ć‚½ćƒ¼ćƒ«āˆ’ļ¼•āˆ’ć‚¤ćƒ«ļ¼‰ć‚·ć‚Æćƒ­ćƒ—ćƒ­ćƒ‘ćƒ³ć‚«ćƒ«ćƒœć‚­ć‚µćƒŸćƒ‰ļ¼‰āˆ’ļ¼“āˆ’ćƒ”ćƒćƒ«ćƒ”ćƒŖć‚øćƒ³āˆ’ļ¼’āˆ’ć‚¤ćƒ«ļ¼‰å®‰ęÆ香é…øć®åŒ»č–¬ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ęŠ•äøŽ
CN102933206A (zh) 2010-04-07 2013-02-13 弗ē‰¹å…‹ę–ÆčÆå“ęœ‰é™å…¬åø 3-(6-(1-(2ļ¼Œ2-äŗŒę°Ÿč‹Æ并[d][1ļ¼Œ3]äŗŒę°§ę‚ēŽÆꈊēƒÆ-5-åŸŗ)ēŽÆäø™ēƒ·ē”²é…°čƒŗåŸŗ)-3-ē”²åŸŗ吔啶-2-åŸŗ)č‹Æē”²é…øēš„å›ŗ体形式
MX342288B (es) 2010-04-22 2016-09-23 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
CA2796602A1 (en) * 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
WO2011133956A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
AU2011242452A1 (en) * 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
EP2787043B1 (fr) 2010-04-30 2018-03-21 Total Marketing Services Utilisation de dƩrivƩs organogelateurs dans des compositions bitumineuses pour amƩliorer leur rƩsistance aux agressions chimiques
AR081920A1 (es) 2010-05-20 2012-10-31 Vertex Pharma Procesos de produccion de moduladores del regulador de conductancia transmembrana de fibrosis quistica
NZ603386A (en) * 2010-05-20 2015-02-27 Vertex Pharma Pharmaceutical compositions and administrations thereof
US8563593B2 (en) * 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
RU2013112937A (ru) 2010-08-23 2014-09-27 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ Š¤Š°Ń€Š¼Š°Ń†ŠµŠ²Ń‚ŠøчŠµŃŠŗŠøŠµ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø (r)-1-(2, 2-Š“ŠøфтŠ¾Ń€Š±ŠµŠ½Š·Š¾[d][1, 3]Š“ŠøŠ¾ŠŗсŠ¾Š»-5-ŠøŠ»)-n-(2, 3-Š“ŠøŠ³ŠøŠ“рŠ¾ŠŗсŠøŠæрŠ¾ŠæŠøŠ»)-6-фтŠ¾Ń€-2-(1-Š³ŠøŠ“рŠ¾ŠŗсŠø-2-Š¼ŠµŃ‚ŠøŠ»ŠæрŠ¾ŠæŠ°Š½-2-ŠøŠ»)-1Š½-ŠøŠ½Š“Š¾Š»-5-ŠøŠ»)цŠøŠŗŠ»Š¾ŠæрŠ¾ŠæŠ°Š½ŠŗŠ°Ń€Š±Š¾ŠŗсŠ°Š¼ŠøŠ“Š° Šø Šøх ŠæрŠøŠ¼ŠµŠ½ŠµŠ½ŠøŠµ
RU2013113627A (ru) 2010-08-27 2014-10-10 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ Š¤Š°Ń€Š¼Š°Ń†ŠµŠ²Ń‚ŠøчŠµŃŠŗŠ°Ń ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøя Šø ŠµŠµ Š²Š²ŠµŠ“ŠµŠ½Šøя
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2773349A1 (en) 2011-11-02 2014-09-10 Vertex Pharmaceuticals Incorporated Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl]- 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide) for treating cftr mediated diseases
US20140127901A1 (en) 2012-11-08 2014-05-08 Taiwan Semiconductor Manufacturing Company, Ltd. Low-k damage free integration scheme for copper interconnects
IN2014KN00885A (zh) * 2011-11-08 2015-10-02 Vertex Pharma
SG10201606135TA (en) 2012-01-25 2016-09-29 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CN104470518A (zh) 2012-02-27 2015-03-25 ę²ƒę³°å…‹ę–ÆčÆē‰©č‚”ä»½ęœ‰é™å…¬åø čÆē‰©ē»„合ē‰©åŠå…¶ę–½ē”Ø
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2858645A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
JP6302923B2 (ja) 2012-11-02 2018-03-28 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ļ¼¶ļ½…ļ½’ļ½”ļ½…ļ½˜ ļ¼°ļ½ˆļ½ļ½’ļ½ļ½ļ½ƒļ½…ļ½•ļ½”ļ½‰ļ½ƒļ½ļ½Œļ½“ ļ¼©ļ½Žļ½ƒļ½ļ½’ļ½ļ½ļ½’ļ½ļ½”ļ½…ļ½„ ļ¼£ļ½†ļ½”ļ½’ćŒåŖ’介恙悋ē–¾ę‚£ć®å‡¦ē½®ć®ćŸć‚ć®åŒ»č–¬ēµ„ęˆē‰©
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
US20160151335A1 (en) 2013-06-26 2016-06-02 Proteostasis Therapeutics, Inc. Methods of modulating cftr activity
RU2016122882A (ru) 2013-11-12 2017-12-19 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ Š”ŠæŠ¾ŃŠ¾Š± ŠæŠ¾Š»ŃƒŃ‡ŠµŠ½Šøя фŠ°Ń€Š¼Š°Ń†ŠµŠ²Ń‚ŠøчŠµŃŠŗŠøх ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠ¹ Š“Š»Ń Š»ŠµŃ‡ŠµŠ½Šøя Š¾ŠæŠ¾ŃŃ€ŠµŠ“Š¾Š²Š°Š½Š½Ń‹Ń… cftr Š·Š°Š±Š¾Š»ŠµŠ²Š°Š½ŠøŠ¹
BR112016013164B1 (pt) 2013-12-27 2022-07-26 Chugai Seiyaku Kabushiki Kaisha PreparaƧƵes sĆ³lidas contendo tofoglifozina e processos para produzir a mesma
ES2957761T3 (es) 2014-04-15 2024-01-25 Vertex Pharma Composiciones farmacƩuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quƭstica
RU2020134082A (ru) 2014-10-06 2020-11-27 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ ŠœŠ¾Š“уŠ»ŃŃ‚Š¾Ń€Ń‹ рŠµŠ³ŃƒŠ»ŃŃ‚Š¾Ń€Š° трŠ°Š½ŃŠ¼ŠµŠ¼Š±Ń€Š°Š½Š½Š¾Š¹ ŠæрŠ¾Š²Š¾Š“ŠøŠ¼Š¾ŃŃ‚Šø ŠæрŠø Š¼ŃƒŠŗŠ¾Š²ŠøсцŠøŠ“Š¾Š·Šµ
JP6746569B2 (ja) 2014-10-07 2020-08-26 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ļ¼¶ļ½…ļ½’ļ½”ļ½…ļ½˜ ļ¼°ļ½ˆļ½ļ½’ļ½ļ½ļ½ƒļ½…ļ½•ļ½”ļ½‰ļ½ƒļ½ļ½Œļ½“ ļ¼©ļ½Žļ½ƒļ½ļ½’ļ½ļ½ļ½’ļ½ļ½”ļ½…ļ½„ åš¢čƒžę€§ē·šē¶­ē—‡č†œč²«é€šć‚³ćƒ³ćƒ€ć‚Æć‚æćƒ³ć‚¹åˆ¶å¾”å› å­ć®ćƒ¢ć‚øćƒ„ćƒ¬ćƒ¼ć‚æćƒ¼ć®å…±ēµę™¶
RU2691136C2 (ru) 2014-11-18 2019-06-11 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ Š”ŠæŠ¾ŃŠ¾Š± ŠæрŠ¾Š²ŠµŠ“ŠµŠ½Šøя Š²Ń‹ŃŠ¾ŠŗŠ¾ŠæрŠ¾ŠøŠ·Š²Š¾Š“ŠøтŠµŠ»ŃŒŠ½Š¾Š¹ тŠµŃŃ‚Š¾Š²Š¾Š¹ Š²Ń‹ŃŠ¾ŠŗŠ¾ŃŃ„Ń„ŠµŠŗтŠøŠ²Š½Š¾Š¹ Š¶ŠøŠ“ŠŗŠ¾ŃŃ‚Š½Š¾Š¹ хрŠ¾Š¼Š°Ń‚Š¾Š³Ń€Š°Ń„ŠøŠø
MA41031A (fr) 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc ConjuguƩs cystƩamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2016086136A1 (en) 2014-11-26 2016-06-02 Catabasis Pharmaceuticals, Inc. Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
WO2016160945A1 (en) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Deuterated vx-661
WO2018183367A1 (en) 2017-03-28 2018-10-04 Van Goor Fredrick F Methods of treating cystic fibrosis in patients with residual function mutations

Also Published As

Publication number Publication date
US20240092766A1 (en) 2024-03-21
CY1116979T1 (el) 2017-04-05
US20150119441A1 (en) 2015-04-30
EP3882245A1 (en) 2021-09-22
PL2007756T3 (pl) 2016-01-29
CN103254177A (zh) 2013-08-21
CY1120045T1 (el) 2018-12-12
US10975061B2 (en) 2021-04-13
SI2007756T1 (sl) 2015-11-30
EP2007756A2 (en) 2008-12-31
ZA200809290B (en) 2009-10-28
PT2007756E (pt) 2015-11-02
PL3091011T3 (pl) 2018-06-29
EP2674428A1 (en) 2013-12-18
JP2009533351A (ja) 2009-09-17
SI2674428T1 (sl) 2016-07-29
US20070244159A1 (en) 2007-10-18
US11639347B2 (en) 2023-05-02
HUE055205T2 (hu) 2021-11-29
EP2674428B1 (en) 2016-04-06
HUE036165T2 (hu) 2018-06-28
CA2648719C (en) 2015-02-24
EP3327016A1 (en) 2018-05-30
CA2648719A1 (en) 2007-10-18
JP5827297B2 (ja) 2015-12-02
HUE026145T2 (en) 2016-05-30
BRPI0710965B1 (pt) 2020-08-18
HUE027630T2 (en) 2016-10-28
EP3091011B1 (en) 2017-12-27
DK3091011T3 (en) 2018-02-26
US8598181B2 (en) 2013-12-03
WO2007117715A3 (en) 2008-01-10
US20220411410A1 (en) 2022-12-29
US20200115366A1 (en) 2020-04-16
PL2674428T3 (pl) 2017-01-31
IL194576A (en) 2016-12-29
LT3091011T (lt) 2018-04-10
SI3091011T1 (en) 2018-06-29
CN101460489A (zh) 2009-06-17
US8912199B2 (en) 2014-12-16
EP3091011A1 (en) 2016-11-09
PL3327016T3 (pl) 2021-10-04
NZ611485A (en) 2014-09-26
NZ596889A (en) 2013-06-28
AU2007235260A1 (en) 2007-10-18
RU2008144124A (ru) 2010-05-20
BRPI0710965B8 (pt) 2021-05-25
CA2869945A1 (en) 2007-10-18
CA2869945C (en) 2018-01-23
DK2674428T3 (en) 2016-04-18
PT2674428T (pt) 2016-07-14
US20180162842A1 (en) 2018-06-14
EP2007756B1 (en) 2015-08-26
US20140057906A1 (en) 2014-02-27
JP5420395B2 (ja) 2014-02-19
ES2659364T3 (es) 2018-03-15
AU2007235260B2 (en) 2013-05-30
US20160332997A1 (en) 2016-11-17
NZ571803A (en) 2011-12-22
US10239867B2 (en) 2019-03-26
CY1117731T1 (el) 2017-05-17
ES2554353T3 (es) 2015-12-18
RU2451018C2 (ru) 2012-05-20
US20100331344A1 (en) 2010-12-30
JP2015120762A (ja) 2015-07-02
BRPI0710965A2 (pt) 2012-01-31
PT3091011T (pt) 2018-03-07
US7776905B2 (en) 2010-08-17
ES2580803T3 (es) 2016-08-26
ES2882684T3 (es) 2021-12-02
IL194576A0 (en) 2009-08-03
DK2007756T3 (en) 2015-10-05
WO2007117715A2 (en) 2007-10-18
US9758510B2 (en) 2017-09-12
MX2008012945A (es) 2009-01-15
SI3327016T1 (sl) 2021-09-30
EP3327016B1 (en) 2021-06-16
JP2014031384A (ja) 2014-02-20

Similar Documents

Publication Publication Date Title
IN2014KN02423A (zh)
MX357497B (es) Moduladores de transportadores de casete de union a atp.
HK1138586A1 (en) Modulators of cftr cftr
WO2010054138A3 (en) Modulators of atp-binding cassette transporters
HK1140475A1 (en) Azaindole derivatives as cftr modulators
WO2009038913A3 (en) Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
HK1148006A1 (en) Isoquinoline modulators of atp-binding cassette transporters atp
WO2006099256A3 (en) Modulators of atp-binding cassette transporters
NZ583878A (en) Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR)
AU2010327993A8 (en) 4-oxo-1H-quinoline-3-carboxamides as modulators of ATP-Binding cassette transporters
WO2007044560A3 (en) Modulators of atp-binding cassette transporters
MX357328B (es) Moduladores de trasportadores de casete enlazante de atp.
MX365890B (es) Moduladores de transportadores con casete de uniĆ³n con atp.
WO2006127588A3 (en) Modulators of atp-binding cassette transporters
WO2009108657A3 (en) Heteroaryl derivatives as cftr modulators
NO20082674L (no) Heterocykliske modulatorer for ATP-bindende kassett-transportere
MX2008002019A (es) Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
DE602004022819D1 (de) Von atp-bindende kassette transportern
WO2005026137A3 (en) Modulators of atp-binding cassette transporters
HK1092353A1 (en) Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
NZ586271A (en) Fused pyrimidinone derivatives as modulators of cystic fibrosis transmembrane conductance regulator
EP2502913A3 (en) Modulators of ATP-binding cassette transporters